Prognostic Significance of Pretreatment Serum Cytokines in Classical Hodgkin Lymphoma
Open Access
- 15 December 2013
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 19 (24) , 6812-6819
Abstract
Purpose: Although the International Prognostic Score (IPS) is the gold standard for risk-stratifying patients with classical Hodgkin lymphoma (cHL), these criteria do not accurately predict outcome. As cytokines are critically involved in driving cHL, we tested whether pretreatment serum cytokine levels could provide additional prognostic information. Experimental Design: Thirty cytokines were measured in pretreatment serum from 140 patients with cHL and compared with 50 nonlymphoma controls. Patients were followed for event-free survival (EFS) and overall survival (OS), and Cox proportional hazards regression models were used to assess the association of individual cytokines and the cytokine profiles with outcome via unadjusted and IPS-adjusted HR. Results: Twelve cytokines (EGF, bFGF, G-CSF, HGF, IL-6, IL-8, IL-12, IL-2R, IP-10, MIG, TNF-α, and VEGF) were significantly (P < 0.05) higher in patients with cHL than controls; elevated levels of HGF, IL-6, IL-2R, IP-10, and MIG were all associated with poorer EFS. Only interleukin-2 receptor (IL-2R; P = 0.002) and interleukin (IL)-6 (P < 0.001) were independently prognostic. Patients with increased IL-6 and IL-2R had a significantly higher risk of early relapse and death, a finding that remained significant even after IPS-based risk stratification. Although elevated IL-6 and IL-2R correlated with the IPS, soluble CD30 (sCD30), and thymus and activation-related chemokine (TARC) levels, the two-cytokine model remained independently predictive of prognosis. Conclusions: Elevated pretreatment serum cytokines are associated with increased disease relapse and inferior survival in cHL. Thus, the pretreatment cytokine profile, particularly serum levels of IL-6 and IL-2R, may be used to identify patients with cHL at high risk for early-disease relapse. Clin Cancer Res; 19(24); 6812–9. ©2013 AACR.Keywords
This publication has 24 references indexed in Scilit:
- Soluble IL-2Rα facilitates IL-2–mediated immune responses and predicts reduced survival in follicular B-cell non-Hodgkin lymphomaBlood, 2011
- Simple: A Sequential Immunoperoxidase Labeling and Erasing MethodJournal of Histochemistry & Cytochemistry, 2009
- Functional coexpression of Interleukin (IL)‐7 and its receptor (IL‐7R) on Hodgkin and Reed‐Sternberg cells: Involvement of IL‐7 in tumor cell growth and microenvironmental interactions of Hodgkin's lymphomaInternational Journal of Cancer, 2009
- Serum YKL-40 and Interleukin 6 Levels in Hodgkin LymphomaClinical Cancer Research, 2008
- Prognostic impact of tumour‐infiltrating Th2 and regulatory T cells in classical Hodgkin lymphomaHematological Oncology, 2008
- Managing relapsed and refractory Hodgkin lymphomaBritish Journal of Haematology, 2008
- Elevated pretreatment interleukin-10 serum level is an International Prognostic Score (IPS)-independent risk factor for early treatment failure in advanced stage Hodgkin lymphomaLeukemia & Lymphoma, 2008
- The AP1-dependent secretion of galectin-1 by Reed–Sternberg cells fosters immune privilege in classical Hodgkin lymphomaProceedings of the National Academy of Sciences, 2007
- IL-6 levels and genotype are associated with risk of young adult Hodgkin lymphomaBlood, 2004
- A Prognostic Score for Advanced Hodgkin's DiseaseNew England Journal of Medicine, 1998